[
    [
        {
            "time": "2018-03-20",
            "original_text": "3家独角兽公司闪电过会，总融资规模将达460多亿",
            "features": {
                "keywords": [
                    "独角兽",
                    "过会",
                    "融资规模"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "3家独角兽公司闪电过会，总融资规模将达460多亿",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-15",
            "original_text": "[推荐评级]医药行业周报：理性解读政策 继续看好Q2行情",
            "features": {
                "keywords": [
                    "医药",
                    "政策",
                    "Q2行情"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级]医药行业周报：理性解读政策 继续看好Q2行情",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-16",
            "original_text": "恒瑞医药：重磅新药将陆续上市 增持评级",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "新药",
                    "上市"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：重磅新药将陆续上市 增持评级",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-17",
            "original_text": "[买入评级]恒瑞医药(600276)点评：业绩增速超预期 重磅创新药有望带动业绩增速加快",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "业绩",
                    "创新药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级]恒瑞医药(600276)点评：业绩增速超预期 重磅创新药有望带动业绩增速加快",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "[看好评级]医药生物行业2018年一季报业绩前瞻：稳健增长 分化明显 重点关注优质成长与稳健价值",
            "features": {
                "keywords": [
                    "医药生物",
                    "业绩",
                    "优质成长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[看好评级]医药生物行业2018年一季报业绩前瞻：稳健增长 分化明显 重点关注优质成长与稳健价值",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "[买入评级]恒瑞医药(600276)年报点评：业绩稳定增长 研发不断加大",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "业绩",
                    "研发"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级]恒瑞医药(600276)年报点评：业绩稳定增长 研发不断加大",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-22",
            "original_text": "[审慎推荐-A评级]恒瑞医药(600276)年报点评：研发投入力度加大 创新和国际化确保持续成长",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "研发投入",
                    "国际化"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[审慎推荐-A评级]恒瑞医药(600276)年报点评：研发投入力度加大 创新和国际化确保持续成长",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-25",
            "original_text": "[买入评级]医药生物行业投资策略：进口抗癌药关税政策无需过度放大 依然看好国内创新药企业",
            "features": {
                "keywords": [
                    "医药生物",
                    "关税政策",
                    "创新药"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级]医药生物行业投资策略：进口抗癌药关税政策无需过度放大 依然看好国内创新药企业",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-28",
            "original_text": "医药界“华为”药明康德发布招股意向书 上市提速(股)",
            "features": {
                "keywords": [
                    "药明康德",
                    "上市",
                    "提速"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药界“华为”药明康德发布招股意向书 上市提速(股)",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-05-02",
            "original_text": "北上资金再现逆势操作 斥资逾18亿元布局9只龙头股",
            "features": {
                "keywords": [
                    "北上资金",
                    "逆势操作",
                    "龙头股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北上资金再现逆势操作 斥资逾18亿元布局9只龙头股",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]